Research programme: respiratory disorders therapeutics - AstraZeneca

Drug Profile

Research programme: respiratory disorders therapeutics - AstraZeneca

Alternative Names: OX-CLI; OX2477

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Orexo
  • Developer AstraZeneca
  • Class
  • Mechanism of Action Leukotriene-C4 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Respiration disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Respiration-disorders in European Union (PO)
  • 17 Mar 2016 AstraZeneca exercises option to acquire OX-CLI research programme
  • 25 Jan 2013 Preclinical trials in Respiration disorders in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top